Can-Fite's Study On Namodenoson's Inhibition of Pancreatic Carcinoma Receives Recognition from the American Society of Clinical Oncology (ASCO)
Portfolio Pulse from Benzinga Newsdesk
Can-Fite BioPharma's study on Namodenoson's inhibition of pancreatic carcinoma has been published in the Journal of Clinical Oncology supplement of the 2023 ASCO Annual Meeting Proceedings. The company focuses on developing small molecule drugs for oncology, inflammatory, and liver diseases.
May 30, 2023 | 11:02 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Can-Fite's study on Namodenoson receives recognition from ASCO, potentially boosting investor confidence in the company's pipeline.
The recognition of Can-Fite's study on Namodenoson by the American Society of Clinical Oncology (ASCO) is a positive development for the company. This recognition may increase investor confidence in Can-Fite's pipeline of small molecule drugs targeting oncology, inflammatory, and liver diseases, potentially leading to a short-term increase in the stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100